Blog

By Akos Roland Toth, Tamas Lakat, Judit Hodrea, Dora B Balogh, Adam Vannay, Laszlo Wagner, Attila Szabo, Andrea Fekete, and Adam Hosszu

Excerpt from the article published in Nephrology Dialysis Transplantation, Volume 37, Issue Supplement_3, May 2022, gfac067.081, https://doi.org/10.1093/ndt/gfac067.081

Editor’s Highlights

• Sigma-1 receptor agonists act directly on proximal tubular cells by activating the S1R-Akt-eNOS signaling pathway and renal vasoregulation.
• Sigma-1 receptor and downstream signaling pathways could provide a novel therapeutic option in Renal ischemia/reperfusion injury (IRI)

Authors previously showed that Sigma-1 receptor (S1R) agonist fluvoxamine treatment is protective against renal IRI (https://doi.org/10.1681/ASN.2015070772).

Abstract

BACKGROUND AND AIMS

Renal ischemia/reperfusion injury (IRI)-induced acute kidney injury is associated with high mortality and morbidity and effective therapies are lacking. We previously showed that Sigma-1 receptor (S1R) agonist fluvoxamine treatment is protective against renal IRI (Hosszu et al, 2017). Here in a rat model, we studied the renoprotective effect of specific, high-affinity S1R agonists focusing on the S1R-Akt-eNOS signaling pathway and renal vasoregulation.

METHOD

8-week old male Wistar rats (n = 8/group) were subjected to 50 min unilateral ischemia with contralateral nephrectomy, kidney tissue was harvested 24 h after reperfusion. 30 min prior to the ischemic insult rats were treated i.p. as follows: (i) isotonic saline as vehicle; (ii) highly specific, high affinity S1R agonist SA-4503; or (iii) SA-4503 + S1R antagonist NE100. Sham-operated rats were used as controls. Renal functional parameters (BUN, serum creatinine, serum aspartate aminotransferase, kidney injury molecule 1 (Kim1), neutrophil gelatinase-associated lipocalin (Ngal) were evaluated. Structural damage was assessed on PAS-stained kidney sections. Renal S1R, phospho-Akt and phospho-eNOS, Hif-1α protein levels and serum nitric oxide (NO) concentration were measured. In vitro experiments were performed on HK2 human proximal tubular epithelial cells treated with a 10 µM dose of S1R agonist SA-4503 or PRE-084.

RESULTS

Impaired kidney function and structural damage after I/R were ameliorated by SA-4503. Expressions of early and sensitive tubular injury markers Kim1 and Ngal were markedly less elevated in SA-4503-treated rats. This recovery was blocked with the addition of the S1R antagonist NE100. S1R, phospho-Akt and phospho-eNOS protein levels were significantly elevated in the kidneys of SA-4503 treated rats. Vasodilator nitric oxide concentration was reduced in the kidney after IRI, but returned to control levels in SA-4503-treated rats. Treatment with S1R agonists SA-4503 and PRE-084 increased the NO production of HK-2 cells.

CONCLUSION

The specific and high-affinity S1R agonist SA-4503 acts directly on proximal tubular cells by activating the S1R-NOS system. Thereby SA-4503 is renoprotective by increasing vasodilative NO production and thus improving post-ischemic renal perfusion. Based on our data activation of S1R and downstream signaling pathways could provide a novel therapeutic option in renal IRI.